- Conditions
- Major Depressive Disorder
- Interventions
- Aripiprazole+ ADT, Placebo+ ADT
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1753–1762
of 1,762
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Major Depressive Disorder, Cardiovascular Diseases, Inflammation, Blood Pressure, Heart Rate Variability
- Interventions
- Single-session emotion regulation training
- Behavioral
- Lead sponsor
- University of Southern Mississippi
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Hattiesburg, Mississippi
- Conditions
- Major Depressive Disorder
- Interventions
- Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Major Depressive Disorder
- Interventions
- Pregnenolone 500 mg, Pregnenolone 800 mg, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Depressive Disorder, Major
- Interventions
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo
- Drug · Other
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 42
- States / cities
- Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Depression
- Interventions
- slow-wave disruption
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 25 Years to 50 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Major Depressive Disorder
- Interventions
- CP-601,927, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 58
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Garden Grove, California + 44 more
- Conditions
- Major Depressive Disorder
- Interventions
- Ropanicant
- Drug
- Lead sponsor
- Suven Life Sciences Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 10
- States / cities
- Bellflower, California • Orange, California • Torrance, California + 7 more
- Conditions
- Major Depressive Disorder
- Interventions
- AXS-05, Bupropion
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 1 more
- Conditions
- Major Depressive Disorder
- Interventions
- REL-1017
- Drug
- Lead sponsor
- Relmada Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 9
- States / cities
- Miami, Florida • Orlando, Florida • Palm Bay, Florida + 4 more